×

Praluent priced on value: Regeneron CEO

8:45 AM ET Mon, 27 July 2015

Leonard Schleifer, Regeneron president & CEO, discusses the FDA's approval of its cholesterol-lowering drug Praluent, and concerns over pricing the new drug. With Jeffrey Sonnenfeld, Yale School of Management.